Tempus AI (NASDAQ:TEM) Shares Up 1.8% – Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM) shares were up 1.8% during trading on Wednesday . The stock traded as high as $48.37 and last traded at $48.05. Approximately 2,138,700 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 5,252,110 shares. The stock had previously closed at $47.22.

Analyst Ratings Changes

A number of research analysts recently weighed in on TEM shares. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Loop Capital reduced their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Needham & Company LLC increased their target price on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Bank of America lifted their price target on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Finally, TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Stock Performance

The firm has a 50-day moving average of $58.64 and a two-hundred day moving average of $51.56. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insiders Place Their Bets

In related news, COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the sale, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at approximately $38,914,527.62. This represents a 2.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the transaction, the chief executive officer now directly owns 4,895,589 shares in the company, valued at $287,615,853.75. This represents a 39.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,598,969 shares of company stock worth $317,194,162 over the last ninety days.

Institutional Trading of Tempus AI

A number of large investors have recently modified their holdings of the company. Operose Advisors LLC acquired a new position in Tempus AI during the 4th quarter valued at about $25,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $34,000. Prestige Wealth Management Group LLC lifted its stake in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at approximately $49,000. Finally, First Horizon Advisors Inc. boosted its position in shares of Tempus AI by 207.9% in the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock worth $55,000 after buying an additional 1,108 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.